Multicenter retrospective analysis of the safety and efficacy of regorafenib after progression on sorafenib in Korean patients with hepatocellular carcinoma
Conclusion Regorafenib was well-tolerated and effective in patients with advanced HCC who progressed on first-line sorafenib, with efficacy and safety outcomes consistent with those of the previous RESORCE trial. TTP on first-line sorafenib may predict the efficacy of subsequent regorafenib.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Cancer & Oncology | Carcinoma | Children | Drugs & Pharmacology | Hepatocellular Carcinoma | Hypertension | Investigational New Drugs | Liver Cancer | Skin | Study | Toxicology